The use of genomic variants to drive drug repurposing for chronic hepatitis B

Irham, Lalu Muhammad and Adikusuma, Wirawan and Perwitasari, Dyah Aryani and Dania, Haafizah and Maliza, Rita and Faridah, Imaniar Noor and Santri, Ichtiarini Nurullita and Abero Phiri, Yohane Vincent and Cheung, Rocky (2022) The use of genomic variants to drive drug repurposing for chronic hepatitis B. Elsevier BV, Biochemistry and Biophysics Reports.

[thumbnail of 8. CAF_The use of genomic.pdf] Text
8. CAF_The use of genomic.pdf
Download (9MB)
[thumbnail of HASIL CEK_Lalu Muhammad Irham, Wirawan Adikusuma, Dyah Aryani Perwitasari, Haafizah Dania, Rita Maliza, Imaniar Noor Faridah, Ichtiarini Nurullita Santri, Yohane Vincent Abero P, Rocky C.pdf] Text
HASIL CEK_Lalu Muhammad Irham, Wirawan Adikusuma, Dyah Aryani Perwitasari, Haafizah Dania, Rita Maliza, Imaniar Noor Faridah, Ichtiarini Nurullita Santri, Yohane Vincent Abero P, Rocky C.pdf
Download (2MB)

Abstract

Background: One of the main challenges in personalized medicine is to establish and apply a large number of
variants from genomic databases into clinical diagnostics and further facilitate genome-driven drug repurposing.
By utilizing biological chronic hepatitis B infection (CHB) risk genes, our study proposed a systematic approach
to use genomic variants to drive drug repurposing for CHB.
Method: The genomic variants were retrieved from the Genome-Wide Association Study (GWAS) and Phenome-
Wide Association Study (PheWAS) databases. Then, the biological CHB risk genes crucial for CHB progression
were prioritized based on the scoring system devised with five strict functional annotation criteria. A score of ≥ 2
were categorized as the biological CHB risk genes and further shed light on drug target genes for CHB treatments.
Overlapping druggable targets were identified using two drug databases (DrugBank and Drug-Gene Interaction
Database (DGIdb)).
Results: A total of 44 biological CHB risk genes were screened based on the scoring system from five functional
annotation criteria. Interestingly, we found 6 druggable targets that overlapped with 18 drugs with status of
undergoing clinical trials for CHB, and 9 druggable targets that overlapped with 20 drugs undergoing preclinical
investigations for CHB. Eight druggable targets were identified, overlapping with 25 drugs that can potentially be
repurposed for CHB. Notably, CD40 and HLA-DPB1 were identified as promising targets for CHB drug repur-
posing based on the target scores.
Conclusion: Through the integration of genomic variants and a bioinformatic approach, our findings suggested
the plausibility of CHB genomic variant-driven drug repurposing for CHB

Item Type: Other
Subjects: R Medicine > RS Pharmacy and materia medica
Divisi / Prodi: Faculty of Pharmacy (Fakultas Farmasi) > S2-Master of Pharmacy (S2-Farmasi)
Depositing User: Lalu Muhammad Irham, M.Farm., Ph.D
Date Deposited: 02 Nov 2022 01:38
Last Modified: 02 Nov 2022 01:38
URI: http://eprints.uad.ac.id/id/eprint/37160

Actions (login required)

View Item View Item